E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute Lymphoblastic Leukemia
|
|
E.1.1.1 | Medical condition in easily understood language |
Acute Lymphoblastic Leukemia
|
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000845 |
E.1.2 | Term | Acute lymphoblastic leukemia |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective for the Phase I portion of the study is to determine the maximum tolerated dose
(MTD), dose limiting toxicities (DLTs), and the recommended Phase II dose (RP2D) of clofarabine when
used in combination with etoposide and cyclophosphamide and to assess the feasibility and safety of this
combination regimen to treat children with refractory or relapsed acute lymphocytic leukemia (ALL) or acute
myelogenous leukemia (AML).
Note: Only the Phase I portion of the study is open to both ALL and AML patients. |
|
E.2.2 | Secondary objectives of the trial |
Phase I portion of the study : to determine the safety and tolerability of clofarabine when used in combination with etoposide (Ep) and cyclophosphamide (Cyp) and to determine the duration, seriousness, and relationship of adverse events that occurred during the treatment and follow-up periods;
•To determine the overall remission (OR) rate (complete remission [CR ]+ CR without
platelet recovery [CRp]) of clofarabine plus Ep and Cyp in pediatric patients with
refractory or relapsed ALL at the established clofarabine RP2D in combination with Ep and Cyp;
• To document the rate of partial remission (PR[s]) in the study population;
• To document time-to-event parameters, including duration of remission, event free survival (EFS),
4-month EFS, and overall survival (OS);and
• To characterize the pharmacodynamics of intracellular clofarabine triphosphate in combination with
etoposide and cyclophosphamide in a subset of patients treated at institutions with sample-processing
expertise. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•NOTE: the following eligibility criteria were applicable to acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) patients for the Phase 1 portion of this study, and to ALL patients for the Phase 2 portion of the study (only ALL patients were allowed in the Phase 2 portion of the study).
•ALL with > 25% blasts in bone marrow; AML with ≥ 5% blasts in bone marrow; ALL and AML patients may have extramedullary disease
•Karnofsky Performance Status ≥ 50 for patients > 10 years old; Lansky Performance Status ≥ 50 for patients ≤ 10 years old
•Prior therapy: AML: 1-2 prior induction regimens and ≤ 1 hematopoietic stem cell transplant (HSCT); ALL: 1-3 prior induction regimens
•Adequate liver, renal, pancreatic, and cardiac function
•Have received no prior HSCT (study amended in Phase 2 to exclude patients with prior HSCT)
|
|
E.4 | Principal exclusion criteria |
•NOTE: the following eligibility criteria were applicable to ALL and AML patients for the Phase 1 portion of this study, and to ALL patients for the Phase 2 portion of the study (only ALL patients were allowed in the Phase 2 portion of the study).
•Burkitt's leukemia
•Previous treatment with clofarabine
•Uncontrolled systemic fungal, bacterial or other infection and 48 hrs negative blood cultures required for patients with a history of fever within 3 days of enrollment
•Active CNS involvement (i.e., should be CNS1 or CNS2)
•Inadequate time since last therapy: ≤ 14 days since last cytotoxic chemotherapy; ≤ 7 days since last biologic therapy; ≤ 14 days since last monoclonal antibody therapy
•Have received prior HSCT (study amended in Phase 2 to exclude patients with prior HSCT)
•Pregnant or lactating
•Have tested positive for hepatitis B or hepatitis C infection or history of cirrhosis
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Maximum Tolerated Dose (MTD) in Phase 1
- Participants With Dose Limiting Toxicity in Phase 1
- Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 2 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- Maximum Tolerated Dose (MTD) in Phase 1: Up to Day 42 (Phase 1 portion of study)
- Participants With Dose Limiting Toxicity in Phase 1: Up to Day 42 (Phase 1 portion of study)
- Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 2: Approximately 28-56 days (Phase 2 portion of study) |
|
E.5.2 | Secondary end point(s) |
1- Summary of Participants With Adverse Events (AEs) in Phase 1
2- Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 1
3- Time to Remission for Participants Who Had a Response in Phase 1
4- Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 1
5- Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 1
6- Number of Participants With 4-month Event Free Survival in Phase 1
7- Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 1
8- Summary of Participants With Adverse Events (AEs) in Phase 2
9- Time to Remission for Participants Who Had a Response in Phase 2
10- Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 2
11- Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 2
12- Number of Participants With 4-month Event Free Survival in Phase 2
13- Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 2
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1- Up to 9.5 months (Phase 1 portion of study)
2- Approximately 2 months
3- Up to 8 weeks (Phase 1 portion of study)
4- Up to 2 years (Phase 1 portion of study)
5- Up to 2 years (Phase 1 portion of study)
6- 4 months (Phase I portion of study)
7- Up to 2 years (Phase 1 portion of study)
8- Up to 9.5 months (Phase 2 portion of study)
9- Up to 8 weeks (Phase 2 portion of study)
10- Up to 2 years (Phase 2 portion of study)
11- Up to 2 years (Phase 2 portion of study)
12- 4 months (Phase 2 portion of study)
13- Up to 2 years (Phase 2 portion of study) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
A Phase I/II Dose-Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial months | 45 |